Teenager with a rare congenital anemia
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Introduction
•The congenital dyserythropoietic anemias are a
rare group of disorders resulting in anemia due to
ineffective erythropoiesis and multinuclear
erythroblasts. It could present in childhood. There are
mainly four different types and genes have been
identified for types I, II and IV and a gene locus
identified for type III.
•CDA type I: Usually caused by homozygous or
compound heterozygous mutation in CDAN1 gene.
Erythroblasts have megaloblastic changes and bony
abnormalities are seen especially in hands and feet.
•CDA type II: Most common form of CDA.
Homozygous or compound heterozygous mutations in
SEC23B gene. The mean age of presentation was
~5yrs and time of diagnosis around 16yrs. Anemia and
jaundice were the main symptoms.
•CDA type III: Characterized by intravascular
hemolysis and large multinucleated erythroblasts.
Most of them with autosomal dominant inheritance.
Mutation in the KIF23 gene.
•CDA type IV: Caused by heterozygous mutation in
the KLF gene.
•Hemosiderosis is a common problem for all types of
CDA due to ineffective erythropoiesis and
inappropriate suppression of hepcidin

Case

Discussion

•Patient is a 16y/o female with history of anemia and jaundice. She
was diagnosed after she was evaluated for recurrent syncopal
episodes since she was about 9yrs of age. These episodes were
usually triggered by heat or cold, or during her periods.
• Family history: Mom with fatty liver disease, no consanguinity
• O/E patient had normal vital signs, wt 54.2kg, ht 157.3cm. Scleral
icterus present.
• CBC is noted below, also had evidence of indirect
hyperbilirubinemia, Tbili 2.8, Dbili 0.2, retic 2.29%
•Peripheral blood smear: Mild anemia with marked red cell
anisopoikilocytosis, possibly from acute stress states such as burn
injury, heat stroke, or alternately from an RBC membrane defect.
•Presence of elliptocytes, dacrocytes, macro-ovalocytes,
microspherocytes, microcytes, rare helmet cells and polychromasia.
•Her iron studies were normal except ferritin 215 ng/mL. Normal vit
B12 and folate levels.
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•Based on these findings a hereditary hemolytic anemia
panel was sent. 2 distinct variants were detected in trans
configuration in the CDAN1 gene.
•Pathogenic variant : nucleic acid change
c.3332+3339del;heterozygous
•Likely pathogenic variant: nucleic acid change
c.3389C>T;heterozygous.
•Pathogenic –mild: UGT1A1, nucleic acid change,
heterozygous
•US abdomen was normal, showed no evidence of gall
stones or splenomegaly.

•Since pathogenic variants in CDAN1 are inherited in an
autosomal recessive manner and are associated with CDA type Ia,
these results are diagnostic of this condition.
• One mildly pathogenic variant was detected in UGT1A1 gene by
massively parallel sequencing. These are inherited in an
autosomal recessive pattern and are associated with type I and
type II Crigler-Najjar syndromes and mild hyperbilirubinemia.
Known as Gilbert’s syndrome.
•Heterozygosity for this variant is associated with partially
decreased UGT1A1 enzyme level but carriers are not expected to
have hyperbilirubinemia. Clinical presentation can be influenced by
other genetic modifiers or coexisting conditions.
•Many of the patients develop splenomegaly and gall stones within
the first 3 decades of life.
•An inadequate reticulocyte response in a patient with congenital
hemolytic anemia may suggest this diagnosis. While the presence
of binucleated normoblasts in the peripheral blood is more specific.

•If the CBC and peripheral smear is suggestive of a mild macrocytic
anemia with evidence of significant anisopoikiloocytosis and hemolysis,
a hereditary hemolytic anemia panel should be strongly considered.
•Once a diagnosis is confirmed patients should be referred for genetic
counseling.They should be closely monitored for iron overload, scoliosis
and osteoporosis.
•Therapy options include splenectomy in type II, interferon alpha in type
I and transfusions for symptomatic patients.
•HSCT is only curative therapy.
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